DNA Script, developer of the SYNTAX System, the first DNA printer using Enzymatic DNA Synthesis (EDS) technology, won the Biotech / Medtech Award from Trophées des Futures Licornes.
“We are delighted to have received the Biotech / Medtech Trophy from the Trophées des Futures Licornes. The entire DNA Script team would like to thank the members of the jury as well as their partners Audacia, Caisse d´Epargne, Deloitte, Euronext, Emlyon Business School, Reputation Age and Scope for this distinction. We would like to thank all of our employees as well as our partners who support us and believe in our vision, which is to democratize access to synthetic DNA,” said the three co-founders of DNA Script: Thomas Ybert, CEO, Sylvain Gariel, COO, and Xavier Godron, CSO.
The Trophées des Futures Licornes recognizes French technology companies with remarkable prospects. The selected companies must meet six criteria: have its head office in France; be under 15 years old; have raised at least 5 million euros since its creation; be an independent, unlisted company; be eligible for one of the five sectors studied; and be valued less than one billion euros.
DNA Script recently partnered with Moderna, as part of a program from DARPA, an agency of the US Department of Defense, to develop a prototype mobile unit for rapid vaccine and therapeutics manufacturing. The programs goal is to develop a “mini-factory” that will make it possible to quickly diagnose and respond to biological threats, producing up to 500 doses of vaccine within three days of deployment. DNA Script was also selected to partner with GE Research as part of a complementary DARPA project (up to $ 9.35 million in funding). Last January, the company signed a similar contract with the French Ministry of the Armed Forces (DGA).